# Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Subjects

> **NCT03150082** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 26 (actual)

## Conditions studied

- Infections, Bacterial

## Interventions

- **DRUG:** GR37547 tablet
- **DRUG:** Ciprofloxacin reference tablet

## Key facts

- **NCT ID:** NCT03150082
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-01
- **Primary completion:** 2017-08-28
- **Final completion:** 2017-08-28
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03150082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03150082, "Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03150082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*